Modern management of pancreatic carcinoma

被引:61
作者
Goldstein, D [1 ]
Carroll, S
Apte, M
Keogh, G
机构
[1] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW 2031, Australia
[2] Prince Wales Hosp, Dept Radiat Oncol, Randwick, NSW 2031, Australia
[3] Prince Wales Hosp, Dept Surg, Randwick, NSW 2031, Australia
[4] Bankstown Lidcombe Hosp, Dept Gastroenterol, Sydney, NSW, Australia
[5] Liverpool Hosp, Dept Gastroenterol, Sydney, NSW, Australia
[6] Univ New S Wales, Sydney, NSW, Australia
关键词
pancreatic cancer; surgery; chemotherapy; radiation therapy; palliative care;
D O I
10.1111/j.1444-0903.2004.00658.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pancreatic cancer remains a fearsome disease. New insights into the molecular pathogenesis may influence choice of treatment modalities and provide avenues for novel therapeutic strategies for testing in the clinic. The survival rate of patients with all stages of disease is poor and clinical trials are appropriate alternatives for treatment and should be considered. Surgical resection, when possible, remains the primary treatment modality and can result in long-term cure. Less invasive techniques such as laparoscopy may reduce the rate of unnecessary laparotomies. The role of adjuvant therapy is re-emerging. Patients with unresectable and metastatic disease are incurable and optimal palliation is the goal. These patients may benefit from palliative bypass of biliary or duodenal obstruction if symptomatic. Pain associated with local tumour infiltration may be palliated with radiation, with or without chemotherapy, or with coeliac nerve blocks or local neurosurgical procedures. Chemotherapy with gemcitabine has modest objective response rates but has been shown to improve symptoms.
引用
收藏
页码:475 / 481
页数:7
相关论文
共 73 条
[1]  
Abbruzzese J.L., 2001, P AN M AM SOC CLIN, V20, P518
[2]  
[Anonymous], 1987, Cancer, V59, P2006
[3]  
[Anonymous], CANC PANCREAS
[4]  
[Anonymous], PANCREAS BIOL PATHOB
[5]   Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 [J].
Berlin, JD ;
Catalano, P ;
Thomas, JP ;
Kugler, JW ;
Haller, DG ;
Benson, AB .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3270-3275
[6]   DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma [J].
Biankin, AV ;
Morey, AL ;
Lee, CS ;
Kench, JG ;
Biankin, SA ;
Hook, HC ;
Head, DR ;
Hugh, TB ;
Sutherland, RL ;
Henshall, SM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) :4531-4542
[7]   Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy [J].
Birkmeyer, JD ;
Finlayson, SRG ;
Tosteson, ANA ;
Sharp, SM ;
Warshaw, AL ;
Fisher, ES .
SURGERY, 1999, 125 (03) :250-256
[8]   Hospital volume and surgical mortality in the United States. [J].
Birkmeyer, JD ;
Siewers, AE ;
Finlayson, EVA ;
Stukel, TA ;
Lucas, FL ;
Batista, I ;
Welch, HG ;
Wennberg, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15) :1128-1137
[9]   TREATMENT AND SURVIVAL IN 13560 PATIENTS WITH PANCREATIC-CANCER, AND INCIDENCE OF THE DISEASE, IN THE WEST MIDLANDS - AN EPIDEMIOLOGIC-STUDY [J].
BRAMHALL, SR ;
ALLUM, WH ;
JONES, AG ;
ALLWOOD, A ;
CUMMINS, C ;
NEOPTOLEMOS, JP .
BRITISH JOURNAL OF SURGERY, 1995, 82 (01) :111-115
[10]   A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J].
Bramhall, SR ;
Schulz, J ;
Nemunaitis, J ;
Brown, PD ;
Baillet, M ;
Buckels, JAC .
BRITISH JOURNAL OF CANCER, 2002, 87 (02) :161-167